NCT00629837已完成1 期
A Randomized, Double-blind, Cross-over Study to Determine the Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980 in Previously Treated Patients With Severe Hemophilia A
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 27
- 试验地点
- 2
- 主要终点
- To determine the pk profile after single administration of two doses of BAY 79-4980 (high and low: 35 IU FVIII/Kg reconstituted in 22 mg and 13 mg of liposomes/kg, respectively) compared to rFVIII-FS (35 IU/Kg reconstituted in 2.5 mL WFI/1000 IU) in PTPs
研究概览
简要总结
The primary objective of this study is to determine the pharmacokinetic profile after single administration of two doses of BAY 79-4980 (high and low: 35 IU FVIII/Kg reconstituted in 22 mg and 13 mg of liposomes/Kg, respectively) compared to rFVIII-FS (35 IU/Kg reconstituted in 2.5 mL WFI/1000 IU) in PTPs aged 12 to 60 years with severe hemophilia A.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 12 Years 至 60 Years（Child, Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Males aged 12 to 60 years
- •Hemophilia A with plasma FVIII level less than 1% (severe hemophilia)
- •No history of FVIII inhibitor antibody formation and no current evidence of inhibitor antibody measured using the Nijmegen modified Bethesda assay (< 0.6 Nijmegen Bethesda Units [N.B.U.]/mL)
- •No signs or symptoms of an acute bleeding episode on the day of infusion
- •Four or more days without treatment with FVIII prior to the day of infusion
- •Subject (or the subject's legal representative) must provide written informed consent and authorization of use and disclosure of Protected Health Information (PHI)
- •Subjects must have been previously treated with FVIII concentrate for a total of at least 200 exposure days, including 20 exposure days in the previous 12 months. Previous treatment can have been with any type of rFVIII or plasma-derived FVIII concentrate
排除标准
- •Individuals with abnormal renal function (serum creatinine concentrations greater than 1.3 mg/dL) or active hepatic disease (persistent aspartate aminotransferase [AST] or alanine aminotransferase [ALT] increases to greater than five times the upper limit of normal).
- •Individuals with anemia, as defined by hemoglobin level less than 12 g/dL
- •Any individual with a past history of severe reaction(s) to FVIII products
- •Any individual on interferon treatment or who has received interferon within the previous 3 months
- •Any individual with thrombocytopenia (platelets greater than or equal to 100,000 cells/mm3) or known hematologic/bleeding problems other than hemophilia A
- •Any individual who is receiving or has received other experimental drugs within 3 months prior to study entry
- •Any individual with known dislipidemic disease or actively taking cholesterol lowering drugs for the treatment of hypercholesterolemia or hyperlipidemia (e.g., statins, cholesterol absorption inhibitors, bile acid sequestrants, nicotinic acid or fibrates) or individuals taking anaesthetic drugs
- •Any individual who requires pre-medication for FVIII infusions (e.g., antihistamines)
- •Any individual with high blood pressure (defined as diastolic blood pressure great than or equal to 100 mm/Hg)
- •Any patient who cannot forego FVIII treatment for at least 4 days prior to study entry or between study infusions due to a need for more frequent prophylactic treatment because of a pre-existing medical condition
- •Any patient with known allergy or severe reactions to liposomes or PEG
- •Individuals with any other known disease affecting hemostasis besides hemophilia A
- •Any patient who is not suitable for participation in this trial for any reason, according to the Investigator
结局指标
主要结局
To determine the pk profile after single administration of two doses of BAY 79-4980 (high and low: 35 IU FVIII/Kg reconstituted in 22 mg and 13 mg of liposomes/kg, respectively) compared to rFVIII-FS (35 IU/Kg reconstituted in 2.5 mL WFI/1000 IU) in PTPs
时间窗: 6 weeks
次要结局
- To determine the infusion tolerability of both BAY 79-4980 doses, by evaluation of vital signs and adverse events(6 weeks)
- To determine the safety of both BAY 79-4980 doses by measuring the effects on laboratory parameters - especially the lipid profile and adverse events(6 weeks)
- To determine the pk characteristics of liposomes - esp body clearance by measuring the major liposome component 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (POPC) and the non-biological liposome component, MPEG 2000 DSPE, as surrogate marker(6 weeks)
- To determine the activity of rFVIII over time (as determined by thrombin generation assay and the rotation thromboelastography [RoTEG] assay) for both doses of BAY 79-4980 compared to rFVIII-FS(6 weeks)
- Additional analyses of the number and timing of spontaneous bleeds after each study treatment will be assessed(6 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Study of the Safety, Tolerability, and Pharmacokinetics of Once Weekly Zicronapine in Patients With SchizophreniaSchizophreniaNCT01377233H. Lundbeck A/S46
已完成
1 期
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-1" and "BR1019-2"Essential HypertensionType 2 Diabetes MellitusNCT06226727Boryung Pharmaceutical Co., Ltd52
已完成
1 期
PK & PD Study of Pegylated rhEPO, and Evaluated Its Safety and Tolerability in Male Healthy IndividualHealthyNCT01800305Xiamen Amoytop Biotech Co., Ltd.150
已完成
1 期
Pharmacokinetics and Safety of PBK-1801 After Single Oral Administration in Healthy Korean WomenHealthy VolunteerNCT04418388Pharmbio Korea Co., Ltd.36
已完成
1 期
Pharmacokinetic Study Of Ibuprofen Injection (IVIb) In Healthy Adult SubjectsHealthyNCT00867880Cumberland Pharmaceuticals12